Skip to main content
Michael Koch, MD, Urology, Indianapolis, IN

Michael O Koch MD FACS

Surgical Oncology


Chairman and Professor of Urology Indiana University School of Medicine

Join to View Full Profile
  • 535 Barnhill Dr# ROUTE420Indianapolis, IN 46202

  • Phone+1 317-944-7338

  • Fax+1 317-278-0499

Dr. Koch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Urology, 1984 - 1987
  • Dartmouth-Hitchcock Medical Center
    Dartmouth-Hitchcock Medical Center1984
  • Geisel School of Medicine at Dartmouth
    Geisel School of Medicine at DartmouthClass of 1981

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1998 - 2025
  • TN State Medical License
    TN State Medical License 1986 - 1999
  • Urology
    American Board of Urology Urology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2011-2015
  • America's Top Doctors for Cancer Castle Connolly, 2010-2015
  • Indianapolis Monthly Castle Connolly, 2007, 2009-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence After Robot-Assisted Radical Prostatectomy with or Without a Small Intestinal Submucosa...  
    Naveen Kella, Michelle A Boger, Michael O Koch, Steven M Lucas, Chandru P Sundaram, Clinton D Bahler, Thomas A Gardner, The Journal of Urology

Lectures

  • AUA Education Workshop for Program Directors and Chairpersons 
    American Urological Association, Linthicum, Maryland - 2/9/2013

Authored Content

  • Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018

Press Mentions

  • Illuccix Approved by FDA as Prostate Cancer Imaging Agent
    Illuccix Approved by FDA as Prostate Cancer Imaging AgentApril 15th, 2022
  • First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
    First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging AgentApril 14th, 2022
  • The End to WHAT Controversy?
    The End to WHAT Controversy?June 24th, 2016
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: